Sign in or create an account to add this stock to your watchlist.
About IntelliPharmaCeutics (NASDAQ:IPCI)
IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001
Debt
Debt-to-Equity RatioN/A
Current Ratio0.29
Quick Ratio0.25
Price-To-Earnings
Trailing P/E Ratio-1.45
Forward P/E Ratio-4.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.51 million
Price / Sales3.24
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book41.00
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-8,850,000.00
Net Margins-217.52%
Return on Equity-2,811.75%
Return on Assets-147.15%
Miscellaneous
Employees62
Outstanding Shares43,540,000
IntelliPharmaCeutics (NASDAQ:IPCI) Frequently Asked Questions
What is IntelliPharmaCeutics' stock symbol?
IntelliPharmaCeutics trades on the NASDAQ under the ticker symbol "IPCI."
How were IntelliPharmaCeutics' earnings last quarter?
IntelliPharmaCeutics (NASDAQ:IPCI) posted its quarterly earnings results on Thursday, October, 13th. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm earned $0.56 million during the quarter, compared to analysts' expectations of $0.50 million. IntelliPharmaCeutics had a negative return on equity of 2,811.75% and a negative net margin of 217.52%. View IntelliPharmaCeutics' Earnings History.
When is IntelliPharmaCeutics' next earnings date?
What price target have analysts set for IPCI?
3 Wall Street analysts have issued twelve-month target prices for IntelliPharmaCeutics' shares. Their forecasts range from $2.00 to $3.10. On average, they anticipate IntelliPharmaCeutics' stock price to reach $2.70 in the next twelve months. View Analyst Ratings for IntelliPharmaCeutics.
What are Wall Street analysts saying about IntelliPharmaCeutics stock?
Here are some recent quotes from research analysts about IntelliPharmaCeutics stock:
- 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (5/8/2018)
- 2. Maxim Group analysts commented, "1Q18 revenues were $0.3M, down from $1.1M in 4Q17 (Nov. YE). The decline owes largely to declining generic Focalin sales, citing pricing pressures in the US generics market. IPCI recently raised $4.5M through an equity financing, which extends the runway into 3Q18. However, we believe that over time the generics business for IPCI will continue to grow and provide revenue that helps offset cash burn associated with key programs: Abuse deterrent Oxycodone and PODRAS (preventing overdose); we view both programs as the long-term drivers of the company." (4/18/2018)
Who are some of IntelliPharmaCeutics' key competitors?
Some companies that are related to IntelliPharmaCeutics include Prima Biomed (IMMP), Elite Pharmaceuticals (ELTP), Novus Therapeutics (NVUS), LifeVantage (LFVN), Pain Therapeutics (PTIE), Vascular Biogenics (VBLT), DiaMedica Therapeutics (DMCAF), Helix Biopharma (HBPCF), Acerus Pharmaceuticals (TRLPF), KaloBios (HGEN), Oasmia Pharmaceutical (OASM), Versartis (VSAR), vTv Therapeutics (VTVT), Alimera Sciences (ALIM) and Addex Pharmaceuticals (ADDXF).
Who are IntelliPharmaCeutics' key executives?
IntelliPharmaCeutics' management team includes the folowing people:
- Dr. Isa Odidi Ph.D., MBA, Co-Founder, Chairman, CEO & Co-Chief Scientist (Age 60)
- Dr. Amina Odidi, Pres, COO, Co-Chief Scientist & Director (Age 58)
- Mr. Andrew P. Patient B.Acc, C.A., Chief Financial Officer (Age 47)
- Dr. Patrick N. Yat, Vice-Pres of Chemistry & Analytical Services (Age 60)
- Mr. Christian Akyempon, VP of Commercial Operations
Has IntelliPharmaCeutics been receiving favorable news coverage?
News coverage about IPCI stock has trended somewhat positive on Friday, according to Accern. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IntelliPharmaCeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 46.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are IntelliPharmaCeutics' major shareholders?
Which institutional investors are buying IntelliPharmaCeutics stock?
How do I buy shares of IntelliPharmaCeutics?
Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IntelliPharmaCeutics' stock price today?
One share of IPCI stock can currently be purchased for approximately $0.41.
How big of a company is IntelliPharmaCeutics?
IntelliPharmaCeutics has a market capitalization of $17.42 million and generates $5.51 million in revenue each year. The company earns $-8,850,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. IntelliPharmaCeutics employs 62 workers across the globe.
How can I contact IntelliPharmaCeutics?
IntelliPharmaCeutics' mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at investors[email protected]
MarketBeat Community Rating for IntelliPharmaCeutics (IPCI)
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
IntelliPharmaCeutics (NASDAQ:IPCI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for IntelliPharmaCeutics in the last 12 months. Their average twelve-month price target is $2.70, suggesting that the stock has a possible upside of 558.54%. The high price target for IPCI is $3.10 and the low price target for IPCI is $2.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.25 | 2.33 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.70 | $2.70 | $2.5250 | $2.3667 |
| Price Target Upside: | 558.54% upside | 409.43% upside | 227.92% upside | 134.32% upside |
IntelliPharmaCeutics (NASDAQ:IPCI) Consensus Price Target History
IntelliPharmaCeutics (NASDAQ:IPCI) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
IntelliPharmaCeutics (NASDAQ:IPCI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
IntelliPharmaCeutics (NASDAQ IPCI) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 25.56%
IntelliPharmaCeutics (NASDAQ IPCI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
IntelliPharmaCeutics (NASDAQ IPCI) News Headlines
| Source: |
|
IntelliPharmaCeutics (NASDAQ:IPCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
IntelliPharmaCeutics (NASDAQ:IPCI) Income Statement, Balance Sheet and Cash Flow Statement
IntelliPharmaCeutics (NASDAQ IPCI) Stock Chart for Friday, May, 25, 2018
Loading chart…
